Guglielmino Gaetano 4

What Happened

• Gaetano Guglielmino, Chief Commercial Officer of Treace Medical Concepts, received a grant of 150,000 restricted stock units (RSUs) on 2026-01-22. The award was granted at $0.00 per share (no cash exchanged) — total immediate cash value $0.
• The RSUs convert to one share of common stock per RSU upon vesting. This is an equity compensation award (retention/incentive), not an open-market purchase or sale.

Key Details

• Transaction date: 2026-01-22; filing date (Form 4): 2026-01-23.
• Grant: 150,000 RSUs at $0.00 (awarded, not purchased).
• Vesting: Equal annual installments over 4 years — first vesting on Jan 22, 2027; final vesting on Jan 22, 2030 — contingent on continued service through each vest date. (Footnote F1)
• Holdings note: Filing footnote indicates this includes 422,250 restricted stock units (F2). The Form 4 does not provide a separate "shares owned after transaction" total beyond that footnote.
• Timeliness: Filed the day after the grant date (appears timely).

Context

• RSUs are a form of deferred equity compensation; they do not represent immediately tradable shares until they vest and convert to common stock. Awards like this are common for senior executives as retention/incentive pay and do not by themselves indicate a buy or sell decision.
• For retail investors, purchases (direct buying of stock) often signal immediate insider conviction; grant awards mainly reflect compensation structure and future dilution risk when they vest and convert to shares.